Resultados da pesquisa - Portal para modelos de dados médicos (portal MDM)

Effect of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on Annual Rate of Exacerbations in Subjects with COPD 102970 - Week 2

- 19/02/2019 - 1 Formulário, 8 Grupos de itens, 17 Elementos de dados, 1 Idioma

Grupos de itens: Administrative documentation, Candidiasis, Examination, Smoking Status, Date of Visit, Assessment Date, Laboratory Procedures, Liver, Adverse Event, Evaluation, Patient withdrawn from trial, Status, Vital Signs, Pre-dose

Study ID: 102970 Clinical Study ID: 102970 Study Title: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01017952 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: GW642444 Inhalation Powder; FF/GW642444 Inhalation Powder Trade Name: Fluticasone Furoate;Fluticasone Propionate;Fluticasone Propionate/Salmeterol;Salmeterol;Vilanterol Study Indication: Pulmonary Disease, Chronic Obstructive

Effect of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on Annual Rate of Exacerbations in Subjects with COPD; 102970 - Week 4

- 19/02/2019 - 1 Formulário, 8 Grupos de itens, 17 Elementos de dados, 1 Idioma

Grupos de itens: Administrative documentation, Candidiasis, Examination, Smoking Status, Date of Visit, Assessment Date, Laboratory Procedures, Liver, Adverse Event, Evaluation, Patient withdrawn from trial, Status, Vital Signs, Pre-dose

Study ID: 102970 Clinical Study ID: 102970 Study Title: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01017952 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: GW642444 Inhalation Powder; FF/GW642444 Inhalation Powder Trade Name: Fluticasone Furoate;Fluticasone Propionate;Fluticasone Propionate/Salmeterol;Salmeterol;Vilanterol Study Indication: Pulmonary Disease, Chronic Obstructive

Systemic exposure of fluticasone propionate (FP) and salmeterol from different inhalation devices in adults with mild or intermittent asthma, (Study-)ID: 101877 - Smoking history, urine cotinine test

- 16/11/2018 - 1 Formulário, 3 Grupos de itens, 8 Elementos de dados, 1 Idioma

Grupos de itens: Administrative data, Smoking History, Urine Cotinine Test

Study ID: 101877 Clinical Study ID: SAS101877 Study Title: A randomised, open label, 5-way crossover study to assess the systemic exposure of FP and salmeterol from SERETIDE/ADVAIR 250 without spacer, with Aerochamber -Plus and with -Max spacer, with VOLUMATIC spacer and SERETIDE/ADVAIR 500 DISKUS/ACCUHALER in adult subjects with mild or intermittent asthma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: fluticasone propionate/salmeterol Trade Name: Advair DISKUS,Seretide Accuhaler; Viani,Seretide Diskus,Seretide Accuhaler,Seretide,Advair DISKUS Study Indication: Asthma The study consists of 5 treatment periods and a follow-up visit. The Screening includes Session 1 Treatment Period 1 includes Session 2 Treatment Period 2 includes Session 3 Treatment Period 3 includes Session 4 Treatment Period 4 includes Session 5 Treatment Period 5 includes Session 6 The Follow-up includes Session 7. This document contains smoking history of subject and urine cotinine test. It has to be filled in at screening.

Alcohol/ Tobacco Use History Screening Ranibizumab Macular Edema Diabetes Mellitus FVF4170g - Alcohol/ Tobacco Use History Screening

- 21/03/2018 - 1 Formulário, 2 Grupos de itens, 15 Elementos de dados, 1 Idioma

Grupos de itens: Smoking History, Alcohol Consumption

Study part: Alcohol/ Tobacco Use History Screening. A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus.

Alcohol/ Tobacco Use History Screening Screening Ranibizumab Macular Edema Diabetes Mellitus FVF4168g - Alcohol/ Tobacco Use History Screening

- 20/03/2018 - 1 Formulário, 2 Grupos de itens, 15 Elementos de dados, 1 Idioma

Grupos de itens: Smoking History, Alcohol Consumption

Study part: Alcohol/ Tobacco Use History Screening. A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus.

Eligibility Cigarette Smoking NCT00736710

- 18/12/2017 - 1 Formulário, 2 Grupos de itens, 9 Elementos de dados, 1 Idioma

Grupos de itens: Inclusion Criteria, Exclusion Criteria

rTMS Effects on Smoking Cessation and Cognition in Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT00736710

Eligibility Cigarette Smoking NCT00554840

- 18/12/2017 - 1 Formulário, 2 Grupos de itens, 19 Elementos de dados, 1 Idioma

Grupos de itens: Inclusion Criteria, Exclusion Criteria

Comparison of Varenicline and Placebo for Smoking Cessation in Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT00554840

Physical exam, Vital signs, Health assessment - GSK Study: GW679769 administered alone vs. with dexamethasone - Evaluation of safety, tolerability and pharmacokinetics NCT00291876

- 16/09/2017 - 1 Formulário, 4 Grupos de itens, 27 Elementos de dados, 1 Idioma

Grupos de itens: Physical Exam, Vital signs, Tobacco history, Alcohol breath test

Physical exam, Vital signs, Health assessment - GSK Study: GW679769 administered alone vs. with dexamethasone - Evaluation of safety, tolerability and pharmacokinetics NCT00291876 Study ID: 100789 Clinical Study ID: NKV100789 Study Title: A two-part, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of single intravenous doses of GW679769 when administered alone and in combination with intravenous or oral doses of dexamethasone in healthy adult subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00291876 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 1 Study Recruitment Status: Completed Generic Name: casopitant Trade Name: Rezonic,Zunrisa; Zunrisa,Rezonic Study Indication: Nausea and Vomiting, Chemotherapy-Induced

Screening and Visit 1 - GSK Study: Hepatitis A & B Vaccine vs. monovalent Hep. A and Hep. B vaccines and risk factors likely to influence their immunogenicity NCT00289731

- 09/09/2017 - 1 Formulário, 17 Grupos de itens, 95 Elementos de dados, 1 Idioma

Grupos de itens: Informed consent, Demographics, Laboratory tests, Eligibility, Inclusion criteria, Exclusion Criteria, Smoking history, Alcohol consumption, Medical history, Disease, Urine sample, Pre-vaccination assessment, Vaccine administration, Vaccine administration, Vaccine administration, Vaccine administration, Serious adverse event - Post-vaccination observation

Screening and Visit 1 - GSK Study: Hepatitis A & B Vaccine vs. monovalent Hep. A and Hep. B vaccines and risk factors likely to influence their immunogenicity NCT00289731 Study ID: 100382 Clinical Study ID: 100382 Study Title: Evaluate the Effect of Several Risk Factors That Are Likely to Influence the Immunogenicity of GSK Biologicals’ Combined Hepatitis A & B Vaccine, vs Separately Administered Monovalent Hepatitis A and Hepatitis B Vaccines Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00289731 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 4 Study Recruitment Status: Completed Generic Name: Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine Trade Name: Twinrix Study Indication: Hepatitis A; Hepatitis B

SMOKING / DRINKING HISTORY Roche H0650g Breast Cancer - SMOKING / DRINKING HISTORY

- 14/05/2017 - 1 Formulário, 2 Grupos de itens, 5 Elementos de dados, 1 Idioma

Grupos de itens: Smoking History, drinking history

Study part: Smoking/ Drinking history. A phase III multinational, randomized, single-blind study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2/neu overexpression who have not received prior cytotoxic chemotherapy for metastatic breast cancer. "Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche"

Palavras-chave

Índice

Modelos de dados selecionados